WuXi XDC out-licenses WuXiTecan-2 payload-linker platform to Ona Therapeutics
WuXi XDC said it has out-licensed its WuXiTecan-2 payload-linker technology platform to Ona Therapeutics to support novel ADC research and development.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.